Lantheus Holdings Stock News

Lantheus (NASDAQ:LNTH) and Global WholeHealth Partners (OTCMKTS:GWHP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings. Valuation & Earnings This table compares Lantheus and Global WholeHealth Partners’ gross revenue, earnings per […] The post Lantheus (NASDAQ:LNTH) versus Global WholeHealth Partners (OTCMKTS:GWHP) Head to Head Contrast appeared first on ETF Daily News .

Lantheus (NASDAQ:LNTH) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It []

Equities analysts forecast that Lantheus Holdings, Inc. (NASDAQ:LNTH) will post earnings of $0.17 per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Lantheus earnings. The highest EPS estimate is $0.17 and the lowest is $0.16. Lantheus posted earnings of $0.07 per share in the same quarter last year, which []

Fisher Asset Management LLC increased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 735.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 373,035 shares of the medical equipment providers stock after acquiring an additional 328,365 shares during the quarter. Fisher []

Crescent Grove Advisors LLC trimmed its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 19.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,798 shares of the medical equipment providers stock after selling 10,000 shares during the quarter. []

Wall Street brokerages forecast that Lantheus Holdings, Inc. (NASDAQ:LNTH) will report sales of $112.85 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Lantheus earnings, with estimates ranging from $112.20 million to $113.50 million. Lantheus posted sales of $94.15 million in the same quarter last year, which would indicate a [] The post $112.85 Million in Sales Expected for Lantheus Holdings, Inc. (NASDAQ:LNTH) This Quarter appeared first on ETF Daily News .

NORTH BILLERICA, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced the appointment of Vivian Yao to its Executive Team as Lantheus Chief Human Resources Officer. Ms. Yao will report directly to Lantheus President and Chief Executive Officer, Mary Anne Heino. In this role, Ms. Yao will oversee all aspects of Lantheus employee and workplace experience, including ensuring best-in-class talent processes, people operations, total rewards, organization effectiveness and next-generation HR capability.

Mitsubishi UFJ Asset Management UK Ltd. acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the third quarter, HoldingsChannel.com reports. The institutional investor acquired 20,000 shares of the medical equipment providers stock, valued at approximately $514,000. Several other hedge funds and other institutional investors have also added to or reduced their stakes in the []

PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans

PYLARIFY is the first and only commercially available, FDA-approved PSMA-targeted PET imaging agent for prostate cancer

Lantheus (NASDAQ:LNTH) updated its FY 2021 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $0.400-$0.430 for the period, compared to the Thomson Reuters consensus estimate of $0.390. The company issued revenue guidance of $405 million-$410 million, compared to the consensus revenue estimate of $396.70 million.Lantheus also updated its Q4 2021 []

Equities analysts expect that Lantheus Holdings, Inc. (NASDAQ:LNTH) will post $112.85 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Lantheus earnings. The highest sales estimate is $113.50 million and the lowest is $112.20 million. Lantheus reported sales of $94.15 million during the same quarter last year, which []

NORTH BILLERICA, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today poster presentations featuring PYLARIFY ® (piflufolastat F 18) data from the Company’s Phase 3 CONDOR study at the upcoming Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), which will be held from November 28 - December 2, 2021 in Chicago, IL and the 22 nd Annual Meeting of the Society for Urologic Oncology (SUO), which will be held from December 1-3, 2021 in Orlando, FL.

NORTH BILLERICA, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, today announced Bob Marshall, Chief Financial Officer and Treasurer, will present at the 4th Annual Evercore ISI HealthCONx Conference at 1:00 p.m. ET on Tuesday, November 30.

NORTH BILLERICA, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagno